Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome
BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of...
Saved in:
Published in | British journal of ophthalmology Vol. 83; no. 10; pp. 1121 - 1124 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
BMA House, Tavistock Square, London, WC1H 9JR
BMJ Publishing Group Ltd
01.10.1999
BMJ BMJ Publishing Group LTD |
Subjects | |
Online Access | Get full text |
ISSN | 0007-1161 1468-2079 |
DOI | 10.1136/bjo.83.10.1121 |
Cover
Loading…
Abstract | BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. METHODS A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days’ treatment, subjects crossed over to the other study medication for a further 28 days’ treatment. RESULTS 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer’s score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. CONCLUSION The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated. |
---|---|
AbstractList | BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. METHODS A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days’ treatment, subjects crossed over to the other study medication for a further 28 days’ treatment. RESULTS 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer’s score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. CONCLUSION The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated. Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome.BACKGROUND/AIMSHyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome.A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment.METHODSA randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment.70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported.RESULTS70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported.The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.CONCLUSIONThe study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated. Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment. 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated. BACKGROUND/AIMS —Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome. METHODS —A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment. RESULTS —70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported. CONCLUSION —The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated. |
Author | Condon, Patrick I McDonald, Carolyn Prescott, Robin J McEwen, Charles G Wright, Mark Mackintosh, Graeme |
AuthorAffiliation | Ardkeen Hospital, Waterford, Ireland |
AuthorAffiliation_xml | – name: Ardkeen Hospital, Waterford, Ireland |
Author_xml | – sequence: 1 givenname: Patrick I surname: Condon fullname: Condon, Patrick I – sequence: 2 givenname: Charles G surname: McEwen fullname: McEwen, Charles G – sequence: 3 givenname: Mark surname: Wright fullname: Wright, Mark – sequence: 4 givenname: Graeme surname: Mackintosh fullname: Mackintosh, Graeme – sequence: 5 givenname: Robin J surname: Prescott fullname: Prescott, Robin J – sequence: 6 givenname: Carolyn surname: McDonald fullname: McDonald, Carolyn |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1976063$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10502570$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUl1v0zAUjdAQ6wavPCJLfGiVls6OGzt9QUIdBaRpSDDGo-XYDnVx7GI7hfw8_hlOW8aYhHiw7Ot7zrnn-vooO7DOqix7jOAEIUzO6pWbVHiyDQt0LxuhKanyAtLZQTaCENIcIYIOs6MQViksCKIPskMES1iUFI6yn-euq40CtdFWngLPrXStDiqd14YLVTsgnI3eGTPcCe9CcBvlT0HbmaiFSjkFQuxkD6IDUkXlW20ViEsFVNNowUUPXAM4SBafg5PvZ5sxCE7qrgXLnpvOO8tjknCmi9pZcLJICnyjgxgDbbc6qQSPbSo1CEnfA9UnQm-ld616mN1vuAnq0X4_zj4tXl_N3-YX79-8m7-6yOsSlTFvaFVVVCEBkYKYF4JKPG2IgGUjmpmUEFVKUCoJmWJMSo4lLqum4qSs8EwUBT7OXu50113dKrntnBu29rrlvmeOa_Z3xuol--I2DNGiqPAg8GIv4N23ToXI0kMLZQy3ynWBkVkBywLDBHx6B7hynbepuaRFZ2lNMU2oJ7f93Bj5PdsEeLYH8CC4adJshQ5_cDNKIMEJNtnBtrP1qrmlxIY_xtIfYxXehQVKhOkdgtCRD7NLbWvzb1q-o-kQ1Y-bItx_ZYRiWrLL6zk7v_744fLz4ooNvsY7fN2u_mfpF_Kl9E4 |
CODEN | BJOPAL |
CitedBy_id | crossref_primary_10_1038_s41598_017_08534_5 crossref_primary_10_1016_j_ajo_2005_05_025 crossref_primary_10_1016_j_carres_2020_107950 crossref_primary_10_3390_ijerph18052383 crossref_primary_10_1007_s40123_017_0110_x crossref_primary_10_3390_nu8110750 crossref_primary_10_1089_108076803321908400 crossref_primary_10_1185_03007995_2015_1125871 crossref_primary_10_1111_cxo_12073 crossref_primary_10_1016_j_rbre_2015_08_002 crossref_primary_10_1097_ICL_0000000000000236 crossref_primary_10_1016_j_colsurfb_2016_01_014 crossref_primary_10_1016_j_clae_2014_09_002 crossref_primary_10_2174_1573412915666190304142952 crossref_primary_10_1038_eye_2017_272 crossref_primary_10_3341_jkos_2023_64_2_170 crossref_primary_10_1016_j_rbr_2015_07_004 crossref_primary_10_3390_genes12030365 crossref_primary_10_1002_mabi_201700261 crossref_primary_10_1007_s00417_004_1040_6 crossref_primary_10_1038_nrrheum_2016_100 crossref_primary_10_1517_13543784_2013_838557 crossref_primary_10_3390_ijms20164031 crossref_primary_10_1097_OPX_0000000000002172 crossref_primary_10_1089_jop_2018_0151 crossref_primary_10_1007_s00432_022_04241_5 crossref_primary_10_1007_s13346_024_01570_5 crossref_primary_10_1002_jbm_a_32481 crossref_primary_10_3390_molecules22122104 crossref_primary_10_1007_s00417_005_0028_1 crossref_primary_10_1016_j_bjps_2007_03_005 crossref_primary_10_1097_ICO_0b013e3181d82f5e crossref_primary_10_1016_j_clae_2013_07_004 crossref_primary_10_1016_j_clae_2017_07_007 crossref_primary_10_1097_ICO_0000000000000155 crossref_primary_10_1097_OPX_0b013e318182476c crossref_primary_10_1016_S0161_6420_02_01219_8 crossref_primary_10_1097_OPX_0000000000002136 crossref_primary_10_1038_srep10248 crossref_primary_10_1111_aos_15675 crossref_primary_10_1155_2014_635490 crossref_primary_10_1111_aos_15159 crossref_primary_10_1016_j_ajpath_2011_10_006 crossref_primary_10_1080_10837450_2024_2345148 crossref_primary_10_1517_14656566_2010_518612 crossref_primary_10_1111_j_1444_0938_2001_tb04930_x crossref_primary_10_1097_ICL_0000000000000284 crossref_primary_10_1111_j_1475_1313_2009_00683_x crossref_primary_10_1016_j_ophtha_2012_12_022 crossref_primary_10_1016_S0142_9612_01_00167_3 crossref_primary_10_1038_nrrheum_2012_53 crossref_primary_10_1038_sj_eye_6700169 |
ContentType | Journal Article |
Copyright | British Journal of Ophthalmology 1999 INIST-CNRS Copyright: 1999 British Journal of Ophthalmology |
Copyright_xml | – notice: British Journal of Ophthalmology – notice: 1999 INIST-CNRS – notice: Copyright: 1999 British Journal of Ophthalmology |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1136/bjo.83.10.1121 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic ProQuest One Academic Middle East (New) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2079 |
EndPage | 1124 |
ExternalDocumentID | PMC1722832 4012639221 10502570 1976063 10_1136_bjo_83_10_1121 ark_67375_NVC_DVSRNWFT_3 bjophthalmol |
Genre | Multicenter Study Comparative Study Clinical Trial Randomized Controlled Trial Journal Article |
GeographicLocations | Edinburgh Scotland |
GeographicLocations_xml | – name: Edinburgh Scotland |
GroupedDBID | --- -~X .55 .GJ .VT 0R~ 18M 23N 2WC 354 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN ABAAH ABJNI ABKDF ABMQD ABTFR ABUWG ABVAJ ACCCW ACGFO ACGFS ACGTL ACHTP ACMFJ ACNCT ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DU5 E3Z EBS EJD F5P FYUFA H13 HAJ HMCUK HYE HZ~ IAO IEA IHR IOF ITC J5H KQ8 L7B M1P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UAW UKHRP UYXKK V24 VM9 W8F WH7 WOQ X7M XOL YFH YQY ZGI 3V. BSCLL RHF AAFWJ AAYXX ACQHZ AERUA CITATION PHGZM IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-b515t-f78887e1c01e03a2c7d34f6c05fcf9dd018ec77d6643365a3d358f8a65839c223 |
IEDL.DBID | BENPR |
ISSN | 0007-1161 |
IngestDate | Thu Aug 21 14:06:33 EDT 2025 Thu Sep 04 17:28:00 EDT 2025 Fri Jul 25 06:22:02 EDT 2025 Thu Jan 02 23:04:31 EST 2025 Mon Jul 21 09:14:13 EDT 2025 Thu Apr 24 23:10:07 EDT 2025 Tue Jul 01 01:47:43 EDT 2025 Wed Oct 30 09:15:11 EDT 2024 Thu Apr 24 23:02:39 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | Human Sodium Compounds Dry eye syndrome Local administration Eye disease Chemotherapy Ophthalmic preparation Randomization Treatment Multicenter study Organic salt Double blind study |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b515t-f78887e1c01e03a2c7d34f6c05fcf9dd018ec77d6643365a3d358f8a65839c223 |
Notes | href:bjophthalmol-83-1121.pdf istex:2D01DC55025071EB02B3FD1795CA030943A9F699 local:bjophthalmol;83/10/1121 PMID:10502570 Carolyn McDonald, Fermentech Medical Ltd, Research Avenue South, Heriot Watt Research Park, Edinburgh EH14 4AP. ark:/67375/NVC-DVSRNWFT-3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://bjo.bmj.com/content/bjophthalmol/83/10/1121.full.pdf |
PMID | 10502570 |
PQID | 1779177437 |
PQPubID | 2041039 |
PageCount | 4 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_1722832 proquest_miscellaneous_69205230 proquest_journals_1779177437 pubmed_primary_10502570 pascalfrancis_primary_1976063 crossref_primary_10_1136_bjo_83_10_1121 crossref_citationtrail_10_1136_bjo_83_10_1121 istex_primary_ark_67375_NVC_DVSRNWFT_3 bmj_primary_10_1136_bjo_83_10_1121 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1999-10-01 |
PublicationDateYYYYMMDD | 1999-10-01 |
PublicationDate_xml | – month: 10 year: 1999 text: 1999-10-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | BMA House, Tavistock Square, London, WC1H 9JR |
PublicationPlace_xml | – name: BMA House, Tavistock Square, London, WC1H 9JR – name: London – name: England |
PublicationTitle | British journal of ophthalmology |
PublicationTitleAlternate | Br J Ophthalmol |
PublicationYear | 1999 |
Publisher | BMJ Publishing Group Ltd BMJ BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group Ltd – name: BMJ – name: BMJ Publishing Group LTD |
References | Fukuda, Miyamoto, Miyara 1998; 10 Tsubota, Yamada 1992; 33 Yokoi, Komuro, Nishida 1997; 81 Stuart, Linn 1985; 17 Hamano, Horimoto, Lee 1996; 40 Polack, McNiece 1982; 1 Nishida, Nakamura, Mishima 1991; 53 Hills, Armitage 1979; 8 Shimmura, Ono, Shinozaki 1995; 79 Van Bijsterweld 1969; 82 Mengher, Pandher, Bron 1986; 70 Sand, Marner, Norn 1989; 67 Wysenbeek, Loya, Sira 1988; 29 Prescott 1981; 30 Ke-Ping, Yukiko, Tsubota 1996; 15 Nakamura, Hikida, Nakano 1993; 12 |
References_xml | – volume: 1 start-page: 133 year: 1982 article-title: The treatment of dry eyes with Na hyaluronate (Healon). publication-title: Cornea – volume: 30 start-page: 9 year: 1981 article-title: The comparison of success rates in cross-over trials in the presence of an order effect. publication-title: Appl Stat – volume: 10 start-page: 20 year: 1998 article-title: Hyaluronic acid in tear fluid and its synthesis by corneal epithelial cells. publication-title: Asia-Pacific J Ophthalmol – volume: 40 start-page: 62 year: 1996 article-title: Sodium hyaluronate eyedrops enhance tear film stability. publication-title: Jpn J Ophthalmol – volume: 15 start-page: 235 year: 1996 article-title: Decrease in corneal sensitivity and change in tear function in dry eye. publication-title: Cornea – volume: 33 start-page: 2942 year: 1992 article-title: Tear evaporation from the ocular surface. publication-title: Invest Ophthalmol Vis Sci – volume: 70 start-page: 442 year: 1986 article-title: Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes. publication-title: Br J Ophthalmol – volume: 79 start-page: 1007 year: 1995 article-title: Sodium hyaluronate eye drops in the treatment of dry eyes. publication-title: Br J Ophthalmol – volume: 17 start-page: 190 year: 1985 article-title: Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders. publication-title: Ann Ophthalmol – volume: 67 start-page: 181 year: 1989 article-title: Sodium hyaluronate in the treatment of keratoconjunctivitis sicca. publication-title: Acta Ophthalmol – volume: 29 start-page: 194 year: 1988 article-title: The effect of sodium on the corneal epithelium. publication-title: Invest Ophthalmol Vis Sci – volume: 53 start-page: 753 year: 1991 article-title: Hyaluronan stimulates corneal epithelial migration. publication-title: Exp Eye Res – volume: 81 start-page: 533 year: 1997 article-title: Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye. publication-title: Br J Ophthalmol – volume: 12 start-page: 433 year: 1993 article-title: Characterization of water retentive properties of hyaluronan. publication-title: Cornea – volume: 82 start-page: 10 year: 1969 article-title: Diagnostic tests in the sicca syndrome. publication-title: Arch Ophthalmol – volume: 8 start-page: 7 year: 1979 article-title: The two-period cross-over clinical trial. publication-title: Br J Clin Pharmacol |
SSID | ssj0002617 |
Score | 1.8596932 |
Snippet | BACKGROUND/AIMS Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study... Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the... BACKGROUND/AIMS —Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref istex bmj |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1121 |
SubjectTerms | Adult Aged Biological and medical sciences Cell adhesion & migration clinical trial Cross-Over Studies Double-Blind Method dry eye Dry Eye Syndromes - drug therapy Eye Female Humans Hyaluronan Hyaluronic Acid - therapeutic use Male Medical sciences Middle Aged Molecular weight Ophthalmic Solutions Original articles - Clinical science Patient Satisfaction Patients Pharmacology. Drug treatments Preferences Sodium Sodium Chloride - therapeutic use Studies Treatment Outcome |
Title | Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome |
URI | http://bjo.bmj.com/content/83/10/1121.full https://api.istex.fr/ark:/67375/NVC-DVSRNWFT-3/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/10502570 https://www.proquest.com/docview/1779177437 https://www.proquest.com/docview/69205230 https://pubmed.ncbi.nlm.nih.gov/PMC1722832 |
Volume | 83 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1tb9MwELZYKyG-IN4X2IqFeNmkZU3iJHY-IRirJqRVaGyj3yzHdrSOLhlNO-jP459xdtxsRbx8axvn4saXu-fOT-4QekmiTKpYFX6ulfJjITOfscQ0M0tzFYgkE6F5OflwmB6cxB9Hycgl3GpHq1zaRGuoVSVNjrwfUgqRBfg7-vbym2-6RpndVddCYw11wQSzpIO67_eHn45aW2zqjTcAmPohgBtXtjEkaT8_r3YZ2W3eognBteQX5yvOqWvu8w9DlhQ13K-iaXTxJyT6O6Hyhoca3EN3HbTE7xpduI9u6fIBun3oNs8fop8AlvOJxjkgS7WD4UKqglXW8Nkys_IKO-L6xPxmp2gInjvYsg7tVTW29WjxrMLKEWk0BgyJtSlFIeQCVwUWGP7tK7z1vX-1jetKjecX-GwhJvOpSdWDCKfueGtg_MLVuJbbeFxaOS3x3QhS0wXWCzjBlVV4hE4G-8d7B77r4ODngJNmfmECbKpDGYQ6ICKSVJG4SGWQFLLIlApCpiWlKgVcRNJEEEUSVjABsIhkEpDLY9Qpq1KvI6wjwSC4iVieQlCjFFM0CWVMAfHouKCph17AAvLLpkYHt7ENSTmsMmek-RqFHvKX68ulq4FuWnFM_jr-TTv-f5JfW3Vph4npV8OZowkfnu7xD6efj4ZfBseceGhzRZ-u5QIwBLzooY2lfnFnTmp-rfweet4eBhUxuzui1NW85mkW2RS_h540ynhjxklgmhV6iK6oaTvAlBhfPVKOz2ypcYC3ppfV039P6hm6Y6tZWI7jBurMpnO9CVhtlvfQGh3RnnssezaZ9gsTYUFl |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLYQlba9TOyeAcOaxgYSoUmcxMnDNG1AVQatJlYub55jO6KsJKxpYf1T-w_7Zzt20kCnXZ54axvXcXWOz_lO_eU7CL0iXiykL1M7UVLaPhexHUWBbmYWJtLhQcxd_XBypxu2D_2PJ8HJHPoxfRZG0yqnMdEEapkL_R9506UUKgvId_TdxTdbd43Sp6vTFhqlW-ypyRWUbMXb3W2w76rntXZ6W2276ipgJ5C7R3aqiz6qXOG4yiHcE1QSPw2FE6QijaV03EgJSmUIuZqEASeSBFEacUjVJBaeFjqAkN8AmBHDLmp82Ol-Oqhjv9Y3LwE3tV0AU5VMpEvCZnKWb0Zks3xqx4VUlpyfzSTDhrbrd03O5AXYJy0ba_wJ-f5O4LyREVsL6H4FZfH70vceoDmVPUR3OtVh_SP0E8B5MlA4ASQrNzDcSObgVQpeGyZYkuOKKD_Qn5klakLpBjYsR3NXhY3-LR7lWFbEHYUBs2KlpS-4mOA8xRzDr13Fa1fNy3Vc5LI_PsenEz4YD_XRAExRbS-81tJ56LJfiHXcz8w8NdFeTySHE6wm8IVKxuExOrwV2z5B81meqWcIK49HUEx5URJCESVlJGngCp8CwlJ-SkMLvQQDsotSE4SZWoqEDKzMIlK-9VwL2VP7MlFpruvWH4O_jn9Tj__fzK-Nu9TD-PCr5ujRgHWPttj20eeD7nGrx4iFlmf86XpeAKKATy20NPUvVoWvgl1vNgut1JfBRfRpEs9UPi5YGHvmSMFCT0tnvLHiwNHNES1EZ9y0HqAlzWevZP1TI20OcFr3znr-70WtoLvtXmef7e929xbRPaOkYfiVS2h-NByrZcCJo-RFtTkx-nLb8eAXsiB7iw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLZQK6G9TLsvGwxrGhtIhCZxEicP07RRKhijQozbm-fYjigrCWtaWP_a3vbPduy4hU67PPHWNq7j6pyc853683cQekWCVMhQ5m6mpHRDLlI3SSLdzCzOpMejlPv6cPJuN946DD-eRCdz6MfkLIymVU5iognUshT6P_KWTylUFpDvaCu3tIi9dufdxTdXd5DSO62Tdhq1i-yo8RWUb9Xb7TbYejkIOpsHG1uu7TDgZpDHh26uC0CqfOH5yiM8EFSSMI-FF-UiT6X0_EQJSmUMeZvEESeSREmecEjbJBWBFj2A8N-kkBWTBmp-2Ozu7U_zgNY6r8E3dX0AVlYy0idxKzsr1xOyXp_g8SGtZednM4mxqW38XRM1eQW2yusmG39Cwb-TOW9kx849dNfCWvy-9sP7aE4VD9D8rt24f4h-AlDP-gpngGrlGoYbyRI8TMFrwwrLSmxJ8339mVmiJpeuYcN4NHdV2Gjh4mGJpSXxKAz4FSstg8HFGJc55hh-7TJeuWpdruKqlL3ROT4d8_5ooLcJYAr7qOGVjs5Jl71KrOJeYeaZku71RHIwxmoMX7CSDo_Q4a3Y9jFqFGWhniKsAp5AYRUkWQwFlZSJpJEvQgpoS4U5jR30EgzILmp9EGbqKhIzsDJLSP028B3kTuzLhNVf121A-n8d_2Y6_n8zvzbuMh3GB181X49GrHu0wdpHn_e7x50DRhy0OONP1_MCKAWs6qCFiX8xG8oqdv3gOWhpehlcRO8s8UKVo4rFaWC2Fxz0pHbGGyuOPN0o0UF0xk2nA7S8-eyVondqZM4BWus-Ws_-vaglNA9xgH3a7u48R3eMqIahWi6gxnAwUosAGYfZC_tsYvTltsPBL1Zqf7c |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Double+blind%2C+randomised%2C+placebo+controlled%2C+crossover%2C+multicentre+study+to+determine+the+efficacy+of+a+0.1%25+%28w%2Fv%29+sodium+hyaluronate+solution+%28Fermavisc%29+in+the+treatment+of+dry+eye+syndrome&rft.jtitle=British+journal+of+ophthalmology&rft.au=Condon%2C+Patrick+I&rft.au=McEwen%2C+Charles+G&rft.au=Wright%2C+Mark&rft.au=Mackintosh%2C+Graeme&rft.date=1999-10-01&rft.issn=0007-1161&rft.eissn=1468-2079&rft.volume=83&rft.issue=10&rft.spage=1121&rft_id=info:doi/10.1136%2Fbjo.83.10.1121&rft_id=info%3Apmid%2F10502570&rft.externalDBID=bjo&rft.externalDocID=bjophthalmol |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1161&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1161&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1161&client=summon |